Hey there! Welcome!
Get updated on
Select Speciality
Top Picks
26 Dec, 25
WCO IOF-ESCEO 2025
This study shows early-life gut microbiome has minimal effect on bone health at age six, though certain taxa and diversity measures were linked to lower BMD and aBMC.
22 Dec, 25
This updated guideline from major respiratory and infectious disease societies recommend shorter all‑oral regimens for drug‑susceptible and drug‑resistant tuberculosis (TB), including novel 4‑month treatments and bedaquiline‑based combinations.
30 Dec, 25Am J Obstet Gynecol.
- 40 RCTs (n≈5,408) included
- Diuretics (7 trials, n=1113) improved BP control with antihypertensives but not alone
- Antihypertensive comparisons (12 trials, n=961) showed enalapril/amlodipine more effective than nifedipine; diltiazem lowered BP vs. nifedipine in severe cases (n=403)
- BP self-monitoring/lifestyle change (9 trials, n=1263) reduced BP at 8 months postpartum.
29 Dec, 25Endocr Pract.
- A study of 124 youths (mean age 12.9 y, T1DM duration 6.0 y; HbA1c 8.1%, glucose TIR 49%) showed mean BMD z-score –0.2 (lower than pediatric norms)
- BMD z-score correlated with BMI z-score (r=0.32, p=0.0002), TIR (r=0.24, p=0.007), 25OHD (r=0.22, p=0.01), & high-impact activity EE (r=0.02, p=0.03)
- 51% of the study population was vit D deficient, vit D deficiency lowered BMD (Δ0.7); activity raised BMD (Δ0.3)
26 Dec, 25Diabetes Obes Metab.
- A meta-analysis of 19 studies (n=1,371,533) found CKD prevalence in T1DM at 22.3%; highest in Americas (27%), lowest in Europe (19.4%)
- Prevalence was higher in adults vs adolescents (20.5% vs 10.5%); with duration ≥10 y vs <10 y (21.8% vs 16.4%); HbA1c ≥8% vs <8% (27.7% vs 17.9%)
- Meta-regression confirmed the link between higher HbA1c & CKD prevalence
- Regular screening is essential to mitigate CKD burden in T1DM.
24 Dec, 25Int J Antimicrob Age...
- Global meta-analysis (2019-23) of 44 studies across 16 countries; largest number of studies were collected from India (n = 9)
- Carbapenem-resistant E. coli prevalence found to be 7%
- NDM was the most common carbapenemase, followed by OXA, KPC, VIM, and IMP.
- Findings highlighted significant global variability. Highest.
12 Dec, 25
Featured
24 Dec, 25
23 Dec, 25
11 Dec, 25
